Cytek Biosciences Inc (CTKB) (Q2 2026) Earnings Call Highlights: Revenue Up 6% to $48. ...

Negative Points

• Cytek Biosciences Inc ( NASDAQ:CTKB ) experienced continued softness in EMEA, with revenue down approximately 8% year-over-year due to ongoing government budgetary pressures from regional geopolitical dynamics.

• Total APAC revenue, excluding China, was flat year-over-year, with softness in other parts of the region offsetting strong growth in China.

• GAAP net loss widened to $12.2 million in Q2 2026 from $5.6 million in the prior year quarter, impacted by higher operating losses, foreign exchange losses, and a non-recurring investment write-off.

• Adjusted EBITDA turned negative at a loss of $1.5 million in Q2 2026, compared to a positive $1.3 million in Q2 2025, due to higher operating expenses and lower investment income.

• Academic and government revenue declined 12% year-over-year to $19.1 million, as strong US growth was offset by weakness in EMEA and other APAC regions.

• The company's strategic reorganization into three business units is expected to take time to yield significant benefits, with the full impact on growth not expected to materialize immediately.

Q & A Highlights

Q: With the biotech funding environment improving, should we expect growth across end markets to equilibrate, and what levers are available to capitalize on recovery in the U.S. versus other geographies? A: CFO William Mccombe noted strong U.S. momentum driven by academic and government customers, while U.S. biopharma was relatively flat in Q2 but up ~20% in the first half. Europe remains challenged due to government R&D funding pressure from shifting spending priorities toward defense. China was strong, and other APAC had a soft quarter but is expected to remain a growth market long-term. Levers include new products like Borealis and Aurora Evo automation, continued investment in sales/marketing infrastructure, and a strong brand position as the leading technology in the space.

Q: What is the annual replacement or retirement rate for the global installed base of 46,000 flow cytometers, and are recent instrument placements competitive upgrades from conventional systems, net new full-spectrum adoption, or expansion within existing accounts? A: CFO William Mccombe cited market reports indicating annual placements of 7,000 to 10,000 units. Cytek plays primarily in the high-end research market, where customers are increasingly shifting toward full-spectrum technology, and the company believes it is continuing to take market share. CEO Wenbin Jiang added that Cytek's growth rate is significantly higher than competitors, suggesting the replacement of conventional cytometers with FSP is working in the company's favor.

Q: Can you provide more detail on the dynamics in China, particularly regarding clinical flow cytometry adoption versus core academic and government areas? A: CFO William Mccombe noted that while Cytek has its Northern Lights instrument clinically approved for hospital use in China, research instruments continue to dominate sales in that market. He highlighted that Cytek remains one of the top three players in the China market based on public data.

Q: Where are you from an operational perspective with the strategic reorganization into three business units, and how soon could benefits translate to the P&L? What is the potential for customer disruption? A: CEO Wenbin Jiang stated the reorganization is in process and expected to be implemented in Q3. The primary objective is aligning resources around different customer segments to improve growth rates and market penetration, particularly in mid/low-end instruments and reagents. Benefits will take time to materialize and are already baked into the 2026 guidance. CFO William Mccombe added that the restructuring should enable better customer service through focused resources and marketing, with no expected disruption.

Q: Why is flow cytometry currently underpenetrated in the clinical space, and what is Cytek's strategy for penetrating the clinical market? A: CFO William Mccombe explained the business unit is called "Solutions and Clinical" because clinical is part of the solutions segment. Cytek serves both true diagnostic and research-clinical markets with panels, reagents, and software optimizations across China, Europe, and the U.S. CEO Wenbin Jiang added that the clinical business is currently small partly because Cytek has approval for clinical products in EMEA and Asia but not yet in the U.S., representing significant potential for future growth.

Q: Have the assumptions for instrument, service, and reagent revenue baked into the guidance shifted from last quarter's framework of continued growth in services/reagents and flat-to-modest growth in instruments? A: CEO Wenbin Jiang confirmed the framework generally holds, with service revenue growing 10% and expected to continue at that level or better. Instrument revenue grew toward the higher end of assumptions. The guidance range is based on a range of scenarios with no major changes to the framework.

Q: Has any of the contingency cushion built into the February guidance been consumed in the first half, and what is the dollar figure for the back half if still assumed? A: CEO Wenbin Jiang stated there is still some contingency in the back half, though the company does not break it out or use a formulaic calculation. He noted the company is growing faster in the first half than implied by the low end or even midpoint of guidance, indicating contingency remains. No changes in market conditions are being forecast.

Q: Can you elaborate on the performance of the newly launched Borealis system and the Aurora Evo automation capabilities, and how they are being received by customers? A: CEO Wenbin Jiang highlighted the Borealis as the industry's first 60-color, seven-laser full-spectral flow cytometer, enabled by proprietary deep UV and IR reagents. It expands cellular biomarker analysis, improves efficiency with nanoparticle analysis and high flow rates, and allows integration of high-parameter cellular imaging. Feedback from early access customers has been very strong. The Aurora Evo configurations add automated and remote operation with an API for interfacing with automation systems, particularly relevant for biopharma and CROs.

Q: What drove the strong U.S. performance in Q2, and how sustainable is this growth across different customer segments? A: CFO William Mccombe reported U.S. revenue of $28.2 million, up 18% year-over-year, driven by impressive growth in equipment revenue from academic and government sectors and the service business. Biopharma in the U.S. was relatively flat in Q2 but up ~20% in the first half, indicating continued strong longer-term growth. The company expects the U.S. to remain a key growth driver.

Q: How is the recurring revenue base evolving, and what is the outlook for service and reagent revenue as a percentage of total revenue? A: CFO William Mccombe noted combined reagent and service revenue was $18.5 million in Q2, up 8% year-over-year, representing 35% of last-12-month revenue, up from 32% a year ago. Service revenue grew 10% to $15.6 million, driven by the expanding installed base and high instrument utilization. The company expects recurring revenue to represent an increasing percentage of total revenue over time.

For the complete transcript of the earnings call, please refer to the full earnings call transcript .